Skip to content
Image above: Adeno-associated viruses
Orbit Biomedical is interested in partnering with companies who are developing single-use therapies for delivery to the subretinal space.
BioTime Enters Into Exclusive Agreement With Orbit Biomedical Ltd. to Access Innovative Device for the Sub-Retinal Delivery of OpRegen® Cells for the Treatment of Dry-AMD
For more information on partnering with us, reach out to us at